PARIS, 04-Oct-2018 — /EuropaWire/ — Sanofi has completed the previously announced divestment of its European generics business Zentiva to Advent International (Advent) effective September 30. The transaction was finalized ahead of schedule for €1,9 billion (enterprise value).
Sanofi announced the beginning of exclusive negotiations with Advent in April of this year and concluded negotiations June 28. The divestiture is part of Sanofi’s strategy to simplify and reshape the company.
About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
SOURCE: Sanofi
Media Relations Contact
Jack Cox
Tel.: +33 (0)1 53 77 46 46
mr@sanofi.com
Investor Relations Contact
George Grofik
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com
(IN BRIEF) The Lenzing Group announces the Lenzing Young Scientist Award at the Dornbirn Global…
(IN BRIEF) Josée Ouellet, Vice President of Services for Alstom in North America, has been…
(IN BRIEF) Alstom was honored with the 2024 Hydrogen Mobility Award at the 2024 Canadian…
(IN BRIEF) Alstom's Innovation Station in Stockholm has initiated a pioneering two-year collaboration with Tåg…
(IN BRIEF) Alstom's industrial site in Catalonia welcomed Spanish Minister of Transport and Sustainable Mobility,…
(IN BRIEF) Evonik has enhanced its capabilities for RESOMER® powder biomaterials at its Darmstadt site…